Analysis of expression data from the CCLE is consistent with the IHC staining and gene-expression analysis of primary tumors (Fig. 1; Supplementary Fig. S1), showing significantly higher MRC2 expression in both STS and bone sarcoma cell lines compared with breast or colorectal cancer cell lines (Fig. 2A). This evidence concerns the gene MRC2 and bone sarcoma.